Merus (MRUS) said late Tuesday it plans an underwritten public offering of its shares, with book-runners including Jefferies, BofA Securities, Leerink Partners and Guggenheim Securities.
The company said it will offer its underwriters a 30-day option to buy up to an additional 15% of the offer shares.
Merus said it plans to use the proceeds for developing drug candidates, clinical research, and general corporate purposes.
Shares were down over 6% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.